Welcome to our dedicated page for BALCHEM SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BALCHEM's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BALCHEM's regulatory disclosures and financial reporting.
BCPC senior vice president and Chief HR Officer Michael Brent Tignor reported multiple equity compensation transactions. On February 11, 2026, he acquired 1,200 shares of restricted common stock at $0, vesting over three years, and 1,929 shares from vested performance stock units for the 2023–2025 period, including 31 dividend equivalent shares.
To cover tax obligations on these vestings, 991 shares were withheld at $178.68 on February 11, 2026 and 165 shares were withheld at $177.49 on February 12, 2026. He also received a stock option for 4,400 shares at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three, expiring on February 11, 2036. Following these transactions he directly held 10,723 common shares, plus 1,456 shares indirectly through a 401(k) plan and 4,400 stock options.
BCPC executive Hatsuki Miyata, EVP, CLO & Secretary, reported several equity compensation transactions. On February 11, 2026, Miyata acquired 1,710 shares of common stock as restricted stock that vests over three years and 2,247 shares from performance stock units for the 2023–2025 period.
To cover related tax liabilities, 877 shares were withheld at $178.68 per share on February 11 and 181 shares were withheld at $177.49 per share on February 12. Miyata also received a grant of 6,300 stock options at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three.
After these transactions, Miyata directly held 8,745 common shares and indirectly held 487 shares through a 401(k) plan, in addition to the 6,300 stock options.
Balchem Corporation executive Carl Martin Bengtsson, EVP & Chief Financial Officer, reported multiple equity compensation transactions and related tax withholdings. On February 11, 2026 he acquired 3,610 shares of common stock as restricted stock and 4,718 shares from vested performance stock units at no cost, while 2,416 of those vested units were withheld to satisfy tax obligations. He also received a stock option grant for 13,200 shares at an exercise price of $178.68 per share, vesting 20% in year one, 40% in year two, and 40% in year three, expiring in 2036. Additional shares were withheld on February 12, 2026 to cover taxes on previously granted restricted shares. After these transactions, he directly held 27,926 common shares, plus 1,086 shares held indirectly in a 401(k) plan, along with 13,200 stock options.
Rigaud Olivier, a director of issuer BCPC, reported an award of restricted common stock. On February 11, 2026, he acquired 870 shares at $0 per share as a grant, increasing his directly held common stock to 2,390 shares after the transaction.
The footnote explains that this restricted stock will vest in the reporting person one year after the grant date, and remains subject to transfer restrictions under a Restricted Stock Grant Agreement between the issuer and the director.
Balchem Corporation director Daniel E. Knutson reported an equity award of company stock. On 02/11/2026, he acquired 870 shares of Balchem common stock as a grant or award at a stated price of $0 per share, increasing his directly held stake to 6,899 shares.
The award is in the form of restricted stock that vests one year after the grant date. Until vesting, the shares are subject to transfer restrictions under a Restricted Stock Grant Agreement between Balchem and Knutson, meaning he must satisfy those conditions before the shares fully vest.
Kathleen B. Fish, a director of the issuer with ticker BCPC, received a grant of 870 shares of common stock on February 11, 2026. The filing classifies this as an acquisition of non-derivative securities at a price of $0 per share.
The 870 shares are restricted stock that will vest one year after the grant date, and are subject to transfer restrictions under a Restricted Stock Grant Agreement between the company and the director. Following this award, Fish beneficially owns 3,429 shares of common stock directly.
Wineinger Matthew David reported acquisition or exercise transactions in a Form 4 filing for BCPC. The filing lists transactions totaling 870 shares. Following the reported transactions, holdings were 8,012 shares.
CORP director David B. Fischer reported an acquisition of common stock through a restricted stock award. On February 11, 2026, he received 870 shares at a price of $0, characterized as a grant or award. These restricted shares vest in one year under a Restricted Stock Grant Agreement with the company. Following this transaction, Fischer directly holds 8,859 shares of CORP common stock.
Director Monica Vicente reported an acquisition of CORP common stock through an equity award. On February 11, 2026, she received 870 shares of restricted common stock at a stated price of $0 per share, increasing her direct holdings to 2,390 shares. According to the footnote, this restricted stock will vest in her name one year after the grant date and is subject to transfer restrictions set out in a Restricted Stock Grant Agreement between CORP and Vicente.
CORP vice president and chief accounting officer William A. Backus reported a routine tax-related share withholding. On 02/08/2026, 322 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares originally granted on 2/8/2023.
After this withholding, Backus beneficially owned 5,517 shares of CORP common stock directly and 283 shares indirectly through a 401(k) plan. The filing reflects administrative share withholding rather than an open-market sale.